Actym Therapeutics is a biotech company that focuses on the discovery and development of novel immuno-oncology therapies to treat cancer.
Actym Therapeutics, Inc. has raised $25.5M in total funding. The most recent round was Series A. The last funding was announced in October 2023.
Actym Therapeutics, Inc.'s investors include Illumina Ventures, Boehringer Ingelheim Venture Fund, Korea Investment Partners, Panacea Venture, Intellectus Partners.
Actym Therapeutics, Inc. is headquartered in Berkeley, United States.
Actym Therapeutics is a biotech company that focuses on the discovery and development of novel immuno-oncology therapies to treat cancer.
Actym Therapeutics, Inc. is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Actym Therapeutics, Inc. — Funding & Investors." VCBacked, October 18, 2023, https://www.vcbacked.co/company/actym-therapeutics-inc. Accessed September 30, 2026.
VCBacked. (2023). Actym Therapeutics, Inc. — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/actym-therapeutics-inc
{{cite web |title=Actym Therapeutics, Inc. — Funding & Investors |url=https://www.vcbacked.co/company/actym-therapeutics-inc |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated